title: [Effect of liangxue shengji recipe on incidence of post-percutaneous coronary intervention restenosis and adverse cardiovascular events].
abstract: OBJECTIVE
  To observe the intervention effect of Liangxue Shengji Recipe (LSR) on incidence of post-percutaneous coronary intervention (post-PCI) restenosis and adverse cardiovascular events.
  
  
  METHODS
  With a randomized, single-blinded methods adopted, 100 patients with coronary artery disease (CHD) and underwent stent implantation were randomized into two groups, the control group and the treated group, conventional Western treatment was administered to them all, but with LSR to patients in the treated group additionally. They were followed up for at least six months. The incidences of post-PCI restenosis and adverse events, including cardiogenic death, acute myocardial infarction, recurrent angina pectoris, severe heart failure, further intervention and coronary artery bypass grafting, were observed to estimate the effect of LSR.
  
  
  RESULTS
  No statistically significant difference between the two groups was shown in terms of incidences of intra-stent restenosis, recurrent angina pectoris, estimator of restenosis and its cumulative risk, as well as in reducing the incidence of single adverse event, but did show statistically significant difference between groups in reducing the incidence of united cardiovascular event (P=0.032) and its cumulative risk (P=0.036).
  
  
  CONCLUSIONS
  Administration of LSR in post-PCI stage could significantly reduce the probability and cumulative risk of united cardiovascular events, and the beneficial effect presents at about six months post-PCI.
authors.affiliation: Department of Cardiovascular Diseases, the Dongfang Hospital Affiliated to Beijing University of Chinese Medicine, Beijing 100078.
authors.forename: Xiao-yun
authors.initials: XY
authors.lastname: Cui
authors.forename: Yang
authors.initials: Y
authors.lastname: Wu
authors.forename: Yi-bing
authors.initials: YB
authors.lastname: Nong
mesh_terms: D015906:Angioplasty, Balloon, Coronary; D003327:Coronary Disease / Q000628:therapy*; D023903:Coronary Restenosis / Q000453:epidemiology / Q000517:prevention & control*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D006349:Heart Valve Diseases / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D015994:Incidence; D008517:Phytotherapy; D012307:Risk Factors; D016037:Single-Blind Method
chemical_list: D004365:Drugs, Chinese Herbal